Research programme: biotherapeutic agent - Parilis Biopharmaceuticals/Outlook Therapeutics
Latest Information Update: 05 Dec 2018
Price :
$50 *
At a glance
- Originator Parilis Biopharmaceuticals
- Developer Outlook Therapeutics; Parilis Biopharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 03 Dec 2018 Oncobiologics is now called Outlook Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 13 Oct 2011 Early research in Undefined indication (unspecified route)